Advertisement

Topics

Sandoz weighs into European rituximab biosimilar market

07:43 EDT 19 Jun 2017 | pharmaphorum

Sandoz has gained European approval for its biosimilar version of Roche's blockbuster MabThera/Rituxan (rituximab) to be called Rixathon. The approval comes hot on the heels of Celltrion’s Truxima, which was the first biosimilar version of the ...

Original Article: Sandoz weighs into European rituximab biosimilar market

NEXT ARTICLE

More From BioPortfolio on "Sandoz weighs into European rituximab biosimilar market"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biosimilars
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...

Monoclonal antibodies MAbs
Monoclonal antibodies recognise and attach to specific proteins produced by cells.  Types of monoclonal antibodies used to treat cancer cells: Block cell dividing dividing signals Transport cancer drugs or radiation to cancer cells Tr...